Investigational drug · Phase 2
FG-B901
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Claudin 18.2, Solid Tumor Malignancies, Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "FG-B901"
First trial start
2026
Jul 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FG-B901", any sponsor or status.
Conditions studied
As listed on its trial records.
- Claudin 18.2
- Solid Tumor Malignancies
- Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FG-B901" as an intervention, largest first.
- A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid TumorsNot yet recruiting
FutureGen Biopharmaceutical (Beijing) Co., LtdIndustry
NCT07623707 · 264 participants (planned) · Start Jul 2026 · Primary completion Dec 2027
Drug: FG-B901; standard or investigator-determined chemotherapy · For: Solid Tumor
Sites: Shanghai, China
- A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid TumorsNot yet recruiting
FutureGen Biopharmaceutical (Beijing) Co., LtdIndustry
NCT07704866 · 120 participants (planned) · Start Jul 30, 2026 · Primary completion Aug 31, 2028
Drug: FG-B901; FG-B901 and 1 more · For: Claudin 18.2; Solid Tumor Malignancies
Sites: Ha’erbin, China; Shenyang, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Claudin 18.2
- FG-M108M108Phase 32 trials
FutureGen Biopharmaceutical (Beijing) Co., Ltd · Claudin 18.2, Solid Tumor Malignancies, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.